MG
CLBT icon

Michael Gelband’s Cellebrite CLBT Stock Holding History

Michael Gelband’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,832
Closed -$664K – 1616
2025
Q4 		$664K Buy
36,832
+20,169
+121% +$362K 0.01% 1117
2025
Q3 		$309K Buy
+16,663
New +$262K ﹤0.01% 1298
2024
Q3 		– Sell
-60,070
Closed -$718K – 1673
2024
Q2 		$718K Sell
60,070
-88,304
-60% -$987K ﹤0.01% 1121
2024
Q1 		$1.64M Sell
148,374
-85,457
-37% -$872K 0.01% 781
2023
Q4 		$2.02M Buy
+233,831
New +$1.82M 0.01% 572
2022
Q1 		– Sell
-24,484
Closed -$196K – 2241
2021
Q4 		$196K Buy
+24,484
New +$231K ﹤0.01% 1836

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Michael Gelband's CLBT Position: Q1 2026 in Review

Michael Gelband sold out of Cellebrite (CLBT) in Q1 2026, closing a stake of 36,832 shares — an estimated $664K sold.

Michael Gelband first reported a position in CLBT in Q4 2021 and held it in 6 quarters. The position peaked at $2.02M in Q4 2023. 221 funds tracked by Wall St. Rank hold CLBT as of Q1 2026.

  • Michael Gelband reported no remaining Cellebrite position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 36,832 Cellebrite shares in Q1 2026, an estimated $664K.
  • Michael Gelband first reported a position in Cellebrite in Q4 2021 and held it in 6 quarters.
  • Michael Gelband's Cellebrite position peaked at $2.02M in Q4 2023.
  • 221 funds tracked by Wall St. Rank held Cellebrite as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.